

4.0.03 DOC Working group minutes

Epilepsies Working Group meeting

Date: 4/01/2024

Location: Virtual

Minutes: Confirmed

Committee members present:

Elizabeth Kay (Chair)	Present for notes 1 – 3
Helen Cross (Topic adviser)	Present for notes 1 – 3
Arjune Sen (Topic adviser)	Present for notes 1 – 3
Rachel Batchelor	Present for notes 1 – 3
Christine Cole	Present for notes 1 – 3
Anita Devlin	Present for notes 1 – 3
Mo Eyeoyibo	Present for notes 1 – 3
Richard Grunewald	Present for notes 1 – 3
Philip Smith	Present for notes 1 – 3
Ashifa Trivedi	Present for notes 1 – 3

In attendance:

Angela Bennett	Director of Guidelines, GDT-NGA	Present for notes 1 – 3
Hilary Eadon	Guideline Lead, GDT- NGA	Present for notes 1 – 3
Eric Power	Programme Director	Present for notes 1 – 3
Louise Bate	Consultant Clinical Adviser	Present for notes 1 – 3
Catharine Baden-Daintree	Senior Medical Editor	Present for notes 1 – 3
Sarah Mee	Senior Medical Assessor, MHRA	Present for notes 1 – 3
Leigh Henderson	Head of Neuropsychiatric disorders, Cognition and Mental Health Safety and Surveillance, MHRA	Present for notes 1 – 3

4.0.03 DOC Working group minutes

1. Welcome and objectives for the meeting

The Chair welcomed the members and attendees to the 1st meeting of the Epilepsies Working Group. The members and attendees introduced themselves.

The Chair informed the Working Group that no apologies had been received.

The Chair outlined the objectives of the meeting, which were to review the recommendations from NG217 about the use of sodium valproate and agree if changes were needed in light of changes made to the regulations by the MHRA.

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was use of sodium valproate for the treatment of epilepsies

A record of the interests declared by Working Group members is available on the NICE website. No new interests were declared at the meeting.

A senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

3. Presentations and discussion

The Chair introduced Sarah Mee, Senior Medical Assessor, MHRA, who gave a presentation on the 2022 CHM review of valproate.

Angela Bennett and Hilary Eadon presented the effectiveness evidence included in NG217 for the different seizure types.

The Working Group then discussed the issues presented in relation to recommendations made for the management of generalised tonic clonic seizures, focal seizures, absence seizures, myoclonic seizures, tonic or atonic seizures, idiopathic generalised epilepsies, Dravet syndrome, Lennox-Gastaut syndrome, infantile spasms syndrome, Doose syndrome and status epilepticus.

Date of next meeting: 10/02/2024

Location of next meeting: Virtual